Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs TransMedics Group Inc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.21 (market cap $4.35B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days and TransMedics Group Inc for 24 Days on average.
| SJNK | TMDX | |
|---|---|---|
Market Cap | $4.35B | $2.74B |
Volume | 3,211,044 | 949,331 |
Sector | Fixed Income | Health |
52-Week High | $25.57 | $150.42 |
52-Week Low | $24.13 | $61.99 |
Typical Hold Time | 41 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.21, showing minimal daily movement with a 0.04% gain. Technical indicators signal bearish momentum with moving averages heavily favoring selling pressure, though oscillators remain neutral. The ETF continues its dividend distribution pattern with recent payments of $0.14-$0.15 per share. Institutional activity shows mixed sentiment with Cetera Investment Advisers maintaining a $17.83 million position while Balefire LLC significantly reduced its holdings by 74.7% in recent quarters.
The ETF faces headwinds from bearish technical signals despite attractive yield comparisons to Treasury bonds. Current price consolidation near $24 support levels suggests cautious investor sentiment. Dividend consistency provides income appeal, but institutional selling pressure and technical weakness indicate near-term challenges for price appreciation amid competitive fixed-income alternatives.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
